Skip to main content
. 2024 Mar 5;24:302. doi: 10.1186/s12885-024-12072-5

Table 2.

Response assessment of third-line treatment

Assessment Chemotherapy ± targeted drugs Anti-angiogenic drugs
(No.)
Total
(No.)
Chemotherapy alone
(No.)
Chemotherapy + targeted drugs
(No.)
PR 12 5 7 1
SD 72 23 49 17
PD 53 27 26 20
ORR 8.8% 9.1% 8.5% 2.6%
DCR 61.3% 50.9% 68.3% 47.4%

CR: complete response, PR: partial response, SD: stable disease, PD: disease progression, ORR: overall response rate, DCR: disease control rate